Literature DB >> 9832297

Cerebrospinal fluid and plasma concentrations of dipyrone metabolites after a single oral dose of dipyrone.

O Cohen1, E Zylber-Katz, Y Caraco, L Granit, M Levy.   

Abstract

OBJECTIVE: Dipyrone is a veteran analgesic and antipyretic drug. After oral administration it is rapidly converted by hydrolysis to 4-methylaminoantipyrine (MAA), which is further metabolized to 4-formylaminoantipyrine (FAA), 4-aminoantipyrine (AA) and 4-acetylaminoantipyrine (AAA). It is still debated whether the site of dipyrone action is in the central nervous system or in the periphery. The purpose of this study was to assess whether dipyrone metabolites cross the blood-brain barrier (BBB) when administered systemically.
METHODS: Twenty-eight patients undergoing diagnostic lumbar puncture (LP) were randomly assigned to receive two 0.5-g dipyrone tablets either 30 min, 1, 1.5, 2, 4, 6, 8 h or 12 h before the lumbar tap. A 5-ml blood sample was drawn concomitantly.
RESULTS: All four metabolites were found in the cerebrospinal fluid (CSF). Their appearance in the CSF lagged but followed that found in the plasma. Mean CSF/plasma ratios were 0.40 (for samples taken between 0.5-2 h) and 0.83 (for samples taken between 4-12 h) for MAA, 0.62 for AA, 0.55 for FAA and 0.40 for AAA (for all samples). Significant correlation was found between plasma and CSF concentrations for MAA, AA, FAA and AAA.
CONCLUSION: The concentration-time course of dipyrone metabolite CSF concentrations are in agreement with that of their plasma concentrations and the analgesic effect of dipyrone.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9832297     DOI: 10.1007/s002280050511

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  7 in total

1.  CB1 receptor-dependent desensitisation of TRPV1 channels contributes to the analgesic effect of dipyrone in sensitised primary sensory neurons.

Authors:  Gilson Goncalves Dos Santos; Ruihui Li; Melissa Pui Een Ng; Julia Borges Paes Lemes; Willians Fernando Vieira; Istvan Nagy; Cláudia Herrera Tambeli; Carlos Amilcar Parada
Journal:  Br J Pharmacol       Date:  2020-09-06       Impact factor: 8.739

2.  Dipyrone metabolite 4-MAA induces hypothermia and inhibits PGE2 -dependent and -independent fever while 4-AA only blocks PGE2 -dependent fever.

Authors:  David do C Malvar; Fernando A Aguiar; Artur de L L Vaz; Débora C R Assis; Miriam C C de Melo; Valquíria A P Jabor; Evanguedes Kalapothakis; Sérgio H Ferreira; Giuliano C Clososki; Glória E P de Souza
Journal:  Br J Pharmacol       Date:  2014-08       Impact factor: 8.739

3.  The antipyretic effect of dipyrone is unrelated to inhibition of PGE(2) synthesis in the hypothalamus.

Authors:  David do C Malvar; Denis M Soares; Aline S C Fabrício; Alexandre Kanashiro; Renes R Machado; Maria J Figueiredo; Giles A Rae; Glória E P de Souza
Journal:  Br J Pharmacol       Date:  2011-03       Impact factor: 8.739

4.  Novel bioactive metabolites of dipyrone (metamizol).

Authors:  Tobias Rogosch; Christian Sinning; Agnes Podlewski; Bernhard Watzer; Joel Schlosburg; Aron H Lichtman; Maria G Cascio; Tiziana Bisogno; Vincenzo Di Marzo; Rolf Nüsing; Peter Imming
Journal:  Bioorg Med Chem       Date:  2011-11-25       Impact factor: 3.641

5.  [Pediatric perioperative systemic pain therapy: Austrian interdisciplinary recommendations on pediatric perioperative pain management].

Authors:  B Messerer; G Grögl; W Stromer; W Jaksch
Journal:  Schmerz       Date:  2014-02       Impact factor: 1.107

6.  COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression.

Authors:  N V Chandrasekharan; Hu Dai; K Lamar Turepu Roos; Nathan K Evanson; Joshua Tomsik; Terry S Elton; Daniel L Simmons
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-19       Impact factor: 11.205

7.  Pharmacokinetics of metamizole (dipyrone) as an add-on in calves undergoing umbilical surgery.

Authors:  Daniela Fux; Moritz Metzner; Johanna Brandl; Melanie Feist; Magdalena Behrendt-Wippermann; Anne von Thaden; Christine Baumgartner
Journal:  PLoS One       Date:  2022-03-15       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.